IM96 CAR-T Cells
Phase 1Cell therapy
IM96 CAR-T Cells is one of 77 biologic programs targeting Adenocarcinoma. It is currently in Phase 1.
3
Indications
3
Total Trials
2
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Eylea
RegeneronPreclinical
Emend IV
Merck & Co.Preclinical
PORTRAZZA
Eli LillyPreclinical
Vascepa
AAmarin Pharma Inc.
Preclinical
Gas-X
PPortuguese Oncology Institute, Coimbra
Preclinical
Ketalar
AAultman Health Foundation
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Andriol
AAuxilium
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Adenocarcinoma1 trial
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction
Not yet recruiting·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1·NCT07406984·18 enrolled
Digestive System Neoplasm1 trial
Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms
Unknown status·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1·NCT05287165·19 enrolled
Colorectal Cancer1 trial
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Colorectal Cancer
Recruiting·BBeijing Immunochina Medical Science & Technology Co., Ltd.·Phase 1·NCT06718738·9 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IM96 CAR-T Cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details